Bristol-Myers Squibb (NYSE:BMY) - Aandelenkoers, Nieuws & Analyse

BMY Overzicht aandelen

Bristol-Myers Squibb Company ontdekt, ontwikkelt, licenseert, produceert, verkoopt, distribueert en verkoopt wereldwijd biofarmaceutische producten. Meer informatie

BMY fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	4/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	4/6

Beloningen

Verhandeld tegen 67.4% onder onze schatting van de reële waarde

De winst zal naar verwachting met 48.75% per jaar groeien

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Heeft een hoog schuldenniveau

Dividend van 4.1% wordt niet goed gedekt door de winst

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Innovative Therapies And Calculated Moves Unlock New Growth Horizons In Pharmaceuticals

Key Takeaways Launch of innovative treatments is poised to drive future revenue by addressing large unmet needs and expanding market presence in various disorders. Strategic acquisitions and a cost savings program aim to enhance growth and net margins through innovation and operational efficiency.

View narrative

US$58.64

0.2% undervalued

-2.07%

Revenue growth p.a.

1 day ago

Bristol-Myers Squibb Company Concurrenten

Zoetis

NYSE:ZTS

US$79.9b

Pfizer

NYSE:PFE

US$151.4b

Merck

NYSE:MRK

US$249.2b

Johnson & Johnson

NYSE:JNJ

US$368.9b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Bristol-Myers Squibb
Historische aandelenkoersen
Huidige aandelenkoers	US$58.50
52 Week Hoogtepunt	US$61.08
52 Week Laag	US$39.35
Bèta	0.44
11 maand verandering	10.88%
3 maanden verandering	18.52%
1 Jaar Verandering	15.07%
33 jaar verandering	-0.91%
5 jaar verandering	2.90%
Verandering sinds IPO	2,637.84%

Recent nieuws en updates

Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren

Oct 28

Recent updates

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Aug 15

Bristol-Myers Squibb: A Potential Comeback In Healthcare

Aug 06

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Jul 27

Bristol Myers Squibb: The More It Drops, The More I Buy

Jul 16

Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?

Jun 13

Bristol Myers: Quality Fundamentals Suppressed By Interest Rates

Jun 09

Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss

Jun 03

Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

May 23

Bristol-Myers Squibb: A Lost Decade?

May 03

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

Apr 29

Is Bristol Myers Squibb A Buy At These Bottom Levels?

Apr 22

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

Apr 12

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

Apr 02

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 21

Bristol-Myers Squibb Is Not A Buy For Me

Mar 19

Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield

Mar 07

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 07

Rendement voor aandeelhouders

	BMY	US Pharmaceuticals	US Markt
7D	6.9%	-1.9%	-0.5%
1Y	15.1%	13.2%	32.3%

Rendement versus industrie: BMY overtrof de US Pharmaceuticals industrie, die het afgelopen jaar een rendement 13.2 % opleverde.

Rendement versus markt: BMY presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 32.3 % opleverde.

Prijsvolatiliteit

Is BMY's price volatile compared to industry and market?
BMY volatility
BMY Average Weekly Movement	4.3%
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.6%
10% least volatile stocks in US Market	3.0%

Stabiele aandelenkoers: BMY heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van BMY is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1887	34,100	Chris Boerner	www.bms.com

Bristol-Myers Squibb Company ontdekt, ontwikkelt, licenseert, produceert, verkoopt, distribueert en verkoopt wereldwijd biofarmaceutische producten. Het bedrijf biedt producten aan voor hematologie, oncologie, cardiovasculaire aandoeningen, immunologie, fibrotische aandoeningen en neurowetenschap. De producten van het bedrijf omvatten Eliquis voor vermindering van het risico op beroerte/systemische embolie bij niet-valvulair atriumfibrilleren en voor de behandeling van DVT/PE; Opdivo voor verschillende indicaties tegen kanker, waaronder blaas-, bloed-, CRC-, hoofd-hals-, RCC-, HCC-, long-, melanoom-, MPM-, maag- en slokdarmkanker; Pomalyst/Imnovid voor multipel myeloom; Orencia voor actieve reumatoïde artritis en artritis psoriatica; en Sprycel voor de behandeling van Philadelphia-chromosoom-positieve chronische myeloïde leukemie.

Bristol-Myers Squibb Company Samenvatting

Hoe verhouden de winst en inkomsten van Bristol-Myers Squibb zich tot de beurswaarde?
BMY fundamentele statistieken
Marktkapitalisatie	US$118.47b
Inkomsten(TTM)	-US$7.26b
Inkomsten(TTM)	US$47.44b

2.5x

P/S-verhouding

-16.3x

Koers/Winstverhouding

Is BMY overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BMY resultatenrekening (TTM)
Inkomsten	US$47.44b
Kosten van inkomsten	US$11.44b
Brutowinst	US$35.99b
Overige uitgaven	US$43.25b
Inkomsten	-US$7.26b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Feb 06, 2025

Winst per aandeel (EPS)	-3.58
Brutomarge	75.87%
Nettowinstmarge	-15.30%
Schuld/Eigen Vermogen Verhouding	289.5%

Hoe presteerde BMY op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

4.1%

Huidig dividendrendement

-67%

Uitbetalingsratio

BMY Overzicht aandelen

Beloningen

Risicoanalyse

Innovative Therapies And Calculated Moves Unlock New Growth Horizons In Pharmaceuticals

Bristol-Myers Squibb Company Concurrenten

NYSE:ZTS

US$79.9b

NYSE:PFE

US$151.4b

NYSE:MRK

US$249.2b

NYSE:JNJ

US$368.9b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Price target increased by 7.4% to US$58.64

Bristol-Myers Squibb Company Showcases the Continued Strength of Its Cardiovascular Portfolio with New Clinical and Real-World Data At American Heart Association Scientific Sessions 2024

Bristol Myers Squibb Presents New Long-Term Data from the EMERGENT Program Evaluating Covenfy in Adults with Schizophrenia At Psych Congress 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data At Psych Congress 2024

Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren

Recent updates

Price target increased by 7.4% to US$58.64

Bristol-Myers Squibb Company Showcases the Continued Strength of Its Cardiovascular Portfolio with New Clinical and Real-World Data At American Heart Association Scientific Sessions 2024

Bristol Myers Squibb Presents New Long-Term Data from the EMERGENT Program Evaluating Covenfy in Adults with Schizophrenia At Psych Congress 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data At Psych Congress 2024

Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren

Bristol-Myers Squibb: A High-Yield Bargain With Growth On The Horizon

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-To-Severe Scalp Psoriasis and in A Real-World Setting

Upcoming dividend of US$0.60 per share

Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)

U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY (xanomeline and Trospium Chlorx), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Bristol Myers Squibb Announces New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from Checkmate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® Plus Yervoy® in Advanced Melanoma

Second quarter dividend of US$0.60 announced

Bristol-Myers Squibb Company to Report Q3, 2024 Results on Oct 31, 2024

Bristol-Myers Still A Value Play Despite Appreciating 26.56% From 2024 Lows

Bristol Myers Squibb Announces Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS (Mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Bristol-Myers Squibb: A Potential Comeback In Healthcare

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Consensus EPS estimates fall by 18%

Bristol-Myers Squibb Company Announces Intangible Asset Impairment Charges for the Three Months Ended June 30, 2024

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb: The More It Drops, The More I Buy

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Bristol-Myers Squibb Company to Report Q2, 2024 Results on Jul 26, 2024

First quarter dividend of US$0.60 announced

Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024

Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024

Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?

Bristol Myers: Quality Fundamentals Suppressed By Interest Rates

Bristol Myers Squibb Announces Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial

Bristol Myers Squibb’S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting

Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine

Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

Bristol Myers Squibb Announces New Four-Year Results from the POETYK PSO Long-Term Extension Trial of Sotyktu (Deucravacitinib) Treatment in Adult Patients with Moderate-To-Severe Plaque Psoriasis

Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol-Myers Squibb: A Lost Decade?

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Bristol Myers Squibb A Buy At These Bottom Levels?

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

Consensus EPS estimates fall by 24%

Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept)

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease